Lifemd, Inc. SEC Filings

LifeMD insider stock award vested: The company's Chief Legal Officer and General Counsel, Eric H. Yecies, had a grant of 50,000 common shares vest on 08/22/2025. The report shows those shares were issued at a $0 per-share price as a performance-based award that vested.

Following this vested award the reporting person beneficially owns 388,900 shares of the issuer's common stock. The Form 4 discloses this as a non-derivative acquisition reflecting the conversion of a performance stock grant into common shares.

LifeMD, Inc. (LFMD) reporting person Dennis Wijnker, identified as an officer with the title Chief Technology Officer, reported a change in beneficial ownership on 08/22/2025. The Form 4 shows a grant of 25,000 shares of common stock that vested on that date with an acquisition price recorded as $0, described as performance stock. After the vesting, the reporting person beneficially owned 175,000 shares. The form is signed and dated 08/26/2025. The filing indicates this was a routine vesting event rather than an open-market purchase or sale.

Maria E. Stan, Chief Accounting Officer of LifeMD, Inc. (LFMD), reported a non‑derivative acquisition of common stock that vested on August 22, 2025. The Form 4 shows a grant of 20,000 shares was recorded as acquired at a price of $0 and the reporting person now beneficially owns 227,500 shares. The filing is signed and dated August 26, 2025. No other transactions or derivative positions are reported.

Insider filing shows grant vesting and holdings Stefan Galluppi, Chief Innovation Officer of LifeMD, Inc. (LFMD), reported an acquisition on 08/22/2025 of 30,000 shares of common stock resulting from a performance stock grant that vested on that date. The reported price is $0, indicating these were shares issued on vesting rather than purchased. After the transaction, Galluppi directly beneficially owns 110,449 shares and indirectly beneficially owns 1,644,800 shares through American Nutra Tech, LLC. The Form 4 was signed on 08/26/2025.

LifeMD insider Jessica Friedeman acquired 50,000 shares of common stock upon vesting of performance stock on 08/22/2025. The Form 4 shows the transaction was reported on 08/26/2025 and lists Friedeman's role as Officer — Chief Marketing Officer. The filing reports 220,000 shares of common stock beneficially owned by the reporting person after the transaction. The acquisition is recorded as non‑derivative, with a reported price of $0 reflecting the vesting of previously granted performance stock.

LifeMD, Inc. reporting person Marc David Benathen, the company's Chief Financial Officer, had 87,000 shares of common stock become vested and were reported as acquired on 08/22/2025 at a reported price of $0, described as performance stock that vested. Following the transaction he beneficially owns 426,554 shares. The Form 4 is filed individually by the reporting person and lists the reporting person's address as LifeMD, Inc., 236 Fifth Avenue, Suite 400, New York, NY 10001.

LifeMD insider stock grant vested: Nicholas P. Alvarez, Chief Acquisition Officer of LifeMD, acquired 100,000 common shares on 08/22/2025 as a result of a performance stock grant that vested. The shares were issued at a $0 price, reflecting a vesting award rather than a purchased transaction. Following this vesting, Alvarez beneficially owns 680,000 common shares in total, held directly. The Form 4 was signed on 08/26/2025.

Insider Form 4 summary: Shayna Webb Dray, listed as Chief Operating Officer and a director-level reporting person at LifeMD, Inc., reported an acquisition on 08/22/2025 of 30,000 shares of the issuer's common stock through the vesting of performance stock. The transaction price is reported as $0, and following the vesting Dray beneficially owns 295,000 shares. The Form 4 was signed on 08/26/2025. The filing indicates the shares were granted as performance stock that vested on the transaction date.